TP53 and plasma cell myeloma: The majority of newly-diagnosed patients with myeloma are felt to have wt p53, but the incidence of deletion at the 17p locus by fluorescence in situ hybridization ranges from 7%–11% [44], [45], and later increases to ∼22% in the relapsed and/or refractory setting [46].